Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China

Abstract People living with HIV (PLWH) bear higher prevalence of HCV coinfection. An accessible directly acting antivirals regimen with less drug–drug interaction with antiretroviral therapy (ART) is urgently needed in source limited regions. We aimed to assess the efficacy and safety of SOF + RBV f...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liyu Chen, Lingyao Du, Shuang Kang, Fanghua Ma, Changmin Li, Min He, Lang Bai, Hong Tang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1df6be1c93a64da084cc854366b80d8b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1df6be1c93a64da084cc854366b80d8b
record_format	dspace
spelling	oai:doaj.org-article:1df6be1c93a64da084cc854366b80d8b2021-12-02T16:53:19ZSofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China10.1038/s41598-021-90706-52045-2322https://doaj.org/article/1df6be1c93a64da084cc854366b80d8b2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-90706-5https://doaj.org/toc/2045-2322Abstract People living with HIV (PLWH) bear higher prevalence of HCV coinfection. An accessible directly acting antivirals regimen with less drug–drug interaction with antiretroviral therapy (ART) is urgently needed in source limited regions. We aimed to assess the efficacy and safety of SOF + RBV for 24 weeks regimen in HIV–HCV coinfected patients in Liangshan Prefecture, China. PLWH under ART from China’s national free antiretroviral treatment project (CNFATP) and diagnosed with treatment-naïve HCV infection were enrolled. SOF + RBV was administrated for 24 weeks and patients were followed for ≥ 12 weeks. The efficacy and safety were analyzed and related factors were explored. 58 patients completed 24 weeks of SOF + RBV and had all tests done. Genotype prevalence in this population was G3 44.8% (n = 26), G6 31.0% (n = 18) and G1 17.2% (n = 10) respectively. 52/58 (89.7%) patients achieved SVR12 while 10.3% experienced therapeutic failure. However, SVR12 was neither significantly different between groups of different gender, age, transmission routines, CD4+ cell count, HIV infection duration, ART duration and HBsAg prevalence nor influenced by HCV viral load, genotypes and hepatic stiffness. The regimen was well-tolerated without any serious AEs or AEs leading to treatment adjustment or discontinuation reported. PLWH in Liangshan showed a high prevalence of HCV coinfection with GT3 and GT6 as the most frequent genotypes. SOF + RBV for 24 weeks could achieve good SVR12 in this population and was well-tolerated. It has great potential to be generalized in coinfected population in source-limited regions.Liyu ChenLingyao DuShuang KangFanghua MaChangmin LiMin HeLang BaiHong TangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Liyu Chen Lingyao Du Shuang Kang Fanghua Ma Changmin Li Min He Lang Bai Hong Tang Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China
description	Abstract People living with HIV (PLWH) bear higher prevalence of HCV coinfection. An accessible directly acting antivirals regimen with less drug–drug interaction with antiretroviral therapy (ART) is urgently needed in source limited regions. We aimed to assess the efficacy and safety of SOF + RBV for 24 weeks regimen in HIV–HCV coinfected patients in Liangshan Prefecture, China. PLWH under ART from China’s national free antiretroviral treatment project (CNFATP) and diagnosed with treatment-naïve HCV infection were enrolled. SOF + RBV was administrated for 24 weeks and patients were followed for ≥ 12 weeks. The efficacy and safety were analyzed and related factors were explored. 58 patients completed 24 weeks of SOF + RBV and had all tests done. Genotype prevalence in this population was G3 44.8% (n = 26), G6 31.0% (n = 18) and G1 17.2% (n = 10) respectively. 52/58 (89.7%) patients achieved SVR12 while 10.3% experienced therapeutic failure. However, SVR12 was neither significantly different between groups of different gender, age, transmission routines, CD4+ cell count, HIV infection duration, ART duration and HBsAg prevalence nor influenced by HCV viral load, genotypes and hepatic stiffness. The regimen was well-tolerated without any serious AEs or AEs leading to treatment adjustment or discontinuation reported. PLWH in Liangshan showed a high prevalence of HCV coinfection with GT3 and GT6 as the most frequent genotypes. SOF + RBV for 24 weeks could achieve good SVR12 in this population and was well-tolerated. It has great potential to be generalized in coinfected population in source-limited regions.
format	article
author	Liyu Chen Lingyao Du Shuang Kang Fanghua Ma Changmin Li Min He Lang Bai Hong Tang
author_facet	Liyu Chen Lingyao Du Shuang Kang Fanghua Ma Changmin Li Min He Lang Bai Hong Tang
author_sort	Liyu Chen
title	Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China
title_short	Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China
title_full	Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China
title_fullStr	Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China
title_full_unstemmed	Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China
title_sort	sofosbuvir plus ribavirin is effective for hcv elimination in people living with hiv from rural area of china
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/1df6be1c93a64da084cc854366b80d8b
work_keys_str_mv	AT liyuchen sofosbuvirplusribaviriniseffectiveforhcveliminationinpeoplelivingwithhivfromruralareaofchina AT lingyaodu sofosbuvirplusribaviriniseffectiveforhcveliminationinpeoplelivingwithhivfromruralareaofchina AT shuangkang sofosbuvirplusribaviriniseffectiveforhcveliminationinpeoplelivingwithhivfromruralareaofchina AT fanghuama sofosbuvirplusribaviriniseffectiveforhcveliminationinpeoplelivingwithhivfromruralareaofchina AT changminli sofosbuvirplusribaviriniseffectiveforhcveliminationinpeoplelivingwithhivfromruralareaofchina AT minhe sofosbuvirplusribaviriniseffectiveforhcveliminationinpeoplelivingwithhivfromruralareaofchina AT langbai sofosbuvirplusribaviriniseffectiveforhcveliminationinpeoplelivingwithhivfromruralareaofchina AT hongtang sofosbuvirplusribaviriniseffectiveforhcveliminationinpeoplelivingwithhivfromruralareaofchina
_version_	1718382844331425792

Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China

Ejemplares similares